1.
Journal of International Oncology
;
(12): 711-714, 2011.
Article
in Chinese
| WPRIM
| ID: wpr-422115
ABSTRACT
Bevacizumab is an efficient and low-toxicity monoclonal antibody towards serum ventricular endothelial growth factor.At present,bevacizumab has been approved by FDA to use clinically for kinds of cancer,such as colorectal cancer,lung cancer,kidney cancer and breast cancer.As more and more patients received bevacizumab cliniclly,it's toxicities are also focused on increasingly.
2.
Chinese Journal of Perinatal Medicine
;
(12)1998.
Article
in Chinese
| WPRIM
| ID: wpr-518066
ABSTRACT
0.05), but there were significant differesnces compared with the control group ( P